What is it about?
Pancreatic cancer is a highly lethal malignancy. However, over the past few decades, therapeutic drugs for pancreatic cancer have yielded very limited success in clinical trials. Signal Transducer and Activator of Transcription-3 (STAT3) is a pro-oncogenic transcription factor. Natural products serve as an inexhaustible source of anticancer drugs. We identified the natural product trienomycin A (TA), an ansamycin antibiotic, as a potential inhibitor of the STAT3 pathway with potent activity against pancreatic cancer.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Pancreatic cancer is an exceptionally fatal disease. However, therapeutic drugs for pancreatic cancer have presented a serious shortage over the past few decades.
Perspectives
Currently, there is a lack of effective therapeutic drugs for pancreatic cancer patients. According to our preliminary study, trienomycin A can be a new potential candidate compound for treating pancreatic cancer, and it is valuable to be further investigated.
Qiu-Rui He
College of Chemistry & Pharmacy, Northwest A&F University
Read the Original
This page is a summary of: The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer, British Journal of Pharmacology, April 2021, Wiley,
DOI: 10.1111/bph.15435.
You can read the full text:
Resources
Contributors
The following have contributed to this page
